By Sheppard Pratt

BALTIMORE , Oct. 13, 2025 /PRNewswire/ -- The Journal of Clinical Psychiatry recently published results from the RECOVER trial, a landmark study examining vagus nerve stimulation (VNS) therapy in individuals with treatment-resistant depression. The analysis, led by Scott T. Aaronson, MD , chief science officer of the Institute for Advanced Diagnostics and Therapeutics at Sheppard Pratt, provides new insight into which patients may be most likely to benefit from this innovative therapy.

The RECOVER trial enrolled 493 adults with markedly treatment-resistant major depressive disorder. On average participants had failed over 13 different treatments in their current episode of depression. All participants were implanted with a vagus nerve stimulation device and we

See Full Page